{"id":"https://openalex.org/W3205572691","doi":"https://doi.org/10.1212/wnl.96.15_supplement.4124","title":"Evobrutinib Efficacy is Maintained Over Two Years in an Open-label Phase II Study Extension in Patients with Relapsing Multiple Sclerosis (4124)","display_name":"Evobrutinib Efficacy is Maintained Over Two Years in an Open-label Phase II Study Extension in Patients with Relapsing Multiple Sclerosis (4124)","publication_year":2021,"publication_date":"2021-04-13","ids":{"openalex":"https://openalex.org/W3205572691","doi":"https://doi.org/10.1212/wnl.96.15_supplement.4124","mag":"3205572691"},"language":"en","primary_location":{"id":"doi:10.1212/wnl.96.15_supplement.4124","doi":"https://doi.org/10.1212/wnl.96.15_supplement.4124","is_oa":false,"landing_page_url":"https://doi.org/10.1212/wnl.96.15_supplement.4124","pdf_url":null,"source":{"id":"https://openalex.org/S79704628","display_name":"Neurology","issn_l":"0028-3878","issn":["0028-3878","1526-632X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neurology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5031171090","display_name":"Xavier Montalb\u00e1n","orcid":"https://orcid.org/0000-0002-0098-9918","observed_orcids":["https://orcid.org/0000-0002-0098-9918"]},"institutions":[{"id":"https://openalex.org/I4210127641","display_name":"Vall d'Hebron Hospital Universitari","ror":"https://ror.org/03ba28x55","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I157913058","https://openalex.org/I4210127641","https://openalex.org/I4210153292"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Xavier Montalban","raw_affiliation_strings":["Vall Hebron University Hospital-Multiple Sclerosis Centre of Catalonia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Vall Hebron University Hospital-Multiple Sclerosis Centre of Catalonia","institution_ids":["https://openalex.org/I4210127641"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065754098","display_name":"Douglas Lorne Arnold","orcid":"https://orcid.org/0000-0003-4266-0106","observed_orcids":["https://orcid.org/0000-0003-4266-0106","https://orcid.org/0000-0002-0805-7672"]},"institutions":[{"id":"https://openalex.org/I1292859797","display_name":"Montreal Neurological Institute and Hospital","ror":"https://ror.org/05ghs6f64","country_code":"CA","type":"healthcare","lineage":["https://openalex.org/I1292859797","https://openalex.org/I2801766832","https://openalex.org/I2801902503","https://openalex.org/I4210139015","https://openalex.org/I4405279980"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"Douglas L. Arnold","raw_affiliation_strings":["Montreal Neurological Institute, McGill Univ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Montreal Neurological Institute, McGill Univ","institution_ids":["https://openalex.org/I1292859797"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100655981","display_name":"Martin S. Weber","orcid":"https://orcid.org/0000-0001-8409-0389","observed_orcids":["https://orcid.org/0000-0001-8409-0389"]},"institutions":[{"id":"https://openalex.org/I74656192","display_name":"University of G\u00f6ttingen","ror":"https://ror.org/01y9bpm73","country_code":"DE","type":"education","lineage":["https://openalex.org/I74656192"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Martin S. Weber","raw_affiliation_strings":["Neurologie & Neuropathologie, Uni Gottingen"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Neurologie & Neuropathologie, Uni Gottingen","institution_ids":["https://openalex.org/I74656192"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108415601","display_name":"Ivan N. Staikov","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2800032632","display_name":"Tokuda Hospital","ror":"https://ror.org/04e61md13","country_code":"BG","type":"healthcare","lineage":["https://openalex.org/I2800032632"]},{"id":"https://openalex.org/I4210093677","display_name":"Acibadem City Clinic","ror":"https://ror.org/00jrbwm32","country_code":"BG","type":"healthcare","lineage":["https://openalex.org/I4210093677"]}],"countries":["BG"],"is_corresponding":false,"raw_author_name":"Ivan Staikov","raw_affiliation_strings":["Department of Neurology, Acibadem City Clinic Tokuda Hospital"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Neurology, Acibadem City Clinic Tokuda Hospital","institution_ids":["https://openalex.org/I2800032632","https://openalex.org/I4210093677"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012486668","display_name":"Karolina Piasecka\u2010Stryczynska","orcid":"https://orcid.org/0000-0001-7000-3256","observed_orcids":["https://orcid.org/0000-0001-7000-3256"]},"institutions":[{"id":"https://openalex.org/I120230055","display_name":"Poznan University of Medical Sciences","ror":"https://ror.org/02zbb2597","country_code":"PL","type":"education","lineage":["https://openalex.org/I120230055"]}],"countries":["PL"],"is_corresponding":false,"raw_author_name":"Karolina Piasecka-Stryczynska","raw_affiliation_strings":["Department of Neurology and Cerebrovascular Diseases, Poznan University Medical Sciences"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Neurology and Cerebrovascular Diseases, Poznan University Medical Sciences","institution_ids":["https://openalex.org/I120230055"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102747029","display_name":"Emily C. Martin","orcid":"https://orcid.org/0000-0002-2011-3905","observed_orcids":["https://orcid.org/0000-0002-2011-3905"]},"institutions":[{"id":"https://openalex.org/I164928964","display_name":"Merck KGaA, Darmstadt (Germany)","ror":"https://ror.org/04b2dty93","country_code":"DE","type":"company","lineage":["https://openalex.org/I164928964"]},{"id":"https://openalex.org/I4405266695","display_name":"Merck Healthcare KGaA, Darmstadt (Germany)","ror":"https://ror.org/04vpzfb52","country_code":"DE","type":"company","lineage":["https://openalex.org/I164928964","https://openalex.org/I4405266695"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Emily C. Martin","raw_affiliation_strings":["Global Clinical Development Center, EMD Serono Research and Development Institute, Inc. (an affiliate of Merck KGaA, Darmstadt, Germany)"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Global Clinical Development Center, EMD Serono Research and Development Institute, Inc. (an affiliate of Merck KGaA, Darmstadt, Germany)","institution_ids":["https://openalex.org/I164928964","https://openalex.org/I4405266695"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5054028850","display_name":"Matthew P. Mandel","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I164928964","display_name":"Merck KGaA, Darmstadt (Germany)","ror":"https://ror.org/04b2dty93","country_code":"DE","type":"company","lineage":["https://openalex.org/I164928964"]},{"id":"https://openalex.org/I4405266695","display_name":"Merck Healthcare KGaA, Darmstadt (Germany)","ror":"https://ror.org/04vpzfb52","country_code":"DE","type":"company","lineage":["https://openalex.org/I164928964","https://openalex.org/I4405266695"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Matthew Mandel","raw_affiliation_strings":["Global Clinical Development Center, EMD Serono Research and Development Institute, Inc. (an affiliate of Merck KGaA, Darmstadt, Germany)"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Global Clinical Development Center, EMD Serono Research and Development Institute, Inc. (an affiliate of Merck KGaA, Darmstadt, Germany)","institution_ids":["https://openalex.org/I164928964","https://openalex.org/I4405266695"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5010771032","display_name":"Fernando Dangond","orcid":"https://orcid.org/0000-0002-6723-4229","observed_orcids":["https://orcid.org/0000-0002-6723-4229"]},"institutions":[{"id":"https://openalex.org/I164928964","display_name":"Merck KGaA, Darmstadt (Germany)","ror":"https://ror.org/04b2dty93","country_code":"DE","type":"company","lineage":["https://openalex.org/I164928964"]},{"id":"https://openalex.org/I4405266695","display_name":"Merck Healthcare KGaA, Darmstadt (Germany)","ror":"https://ror.org/04vpzfb52","country_code":"DE","type":"company","lineage":["https://openalex.org/I164928964","https://openalex.org/I4405266695"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Fernando Dangond","raw_affiliation_strings":["Global Clinical Development Center, EMD Serono Research and Development Institute, Inc. (an affiliate of Merck KGaA, Darmstadt, Germany)"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Global Clinical Development Center, EMD Serono Research and Development Institute, Inc. (an affiliate of Merck KGaA, Darmstadt, Germany)","institution_ids":["https://openalex.org/I164928964","https://openalex.org/I4405266695"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5076338840","display_name":"Jerry S. Wolinsky","orcid":"https://orcid.org/0000-0002-8197-2762","observed_orcids":["https://orcid.org/0000-0002-8197-2762"]},"institutions":[{"id":"https://openalex.org/I919571938","display_name":"The University of Texas Health Science Center at Houston","ror":"https://ror.org/03gds6c39","country_code":"US","type":"education","lineage":["https://openalex.org/I919571938"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jerry S. Wolinsky","raw_affiliation_strings":["McGovern Medical School, UTHealth"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"McGovern Medical School, UTHealth","institution_ids":["https://openalex.org/I919571938"]}]}],"institutions":[],"countries_distinct_count":6,"institutions_distinct_count":9,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.8331,"has_fulltext":false,"cited_by_count":5,"citation_normalized_percentile":{"value":0.71178368,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":96},"biblio":{"volume":"96","issue":"15_supplement","first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10137","display_name":"Multiple Sclerosis Research Studies","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10137","display_name":"Multiple Sclerosis Research Studies","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10469","display_name":"Psoriasis: Treatment and Pathogenesis","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/evobrutinib","display_name":"evobrutinib","score":1.0},{"id":"https://openalex.org/keywords/relapsing-multiple-sclerosis","display_name":"relapsing multiple sclerosis","score":0.996999979019165},{"id":"https://openalex.org/keywords/long-term-efficacy","display_name":"long-term efficacy","score":0.9459999799728394},{"id":"https://openalex.org/keywords/open-label-extension","display_name":"open-label extension","score":0.9190000295639038},{"id":"https://openalex.org/keywords/bruton-tyrosine-kinase-inhibitors","display_name":"BTK inhibitors","score":0.671999990940094}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5018489360809326},{"id":"https://openalex.org/C2780640218","wikidata":"https://www.wikidata.org/wiki/Q8277","display_name":"Multiple sclerosis","level":2,"score":0.4566570520401001},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.15093696117401123}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1212/wnl.96.15_supplement.4124","doi":"https://doi.org/10.1212/wnl.96.15_supplement.4124","is_oa":false,"landing_page_url":"https://doi.org/10.1212/wnl.96.15_supplement.4124","pdf_url":null,"source":{"id":"https://openalex.org/S79704628","display_name":"Neurology","issn_l":"0028-3878","issn":["0028-3878","1526-632X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neurology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4367304943","https://openalex.org/W4389464500","https://openalex.org/W4392376725","https://openalex.org/W4389366547","https://openalex.org/W4389883767","https://openalex.org/W4362472973","https://openalex.org/W4389448039","https://openalex.org/W2966319593","https://openalex.org/W3188387885","https://openalex.org/W4402630414"],"abstract_inverted_index":{"Objective:":[0],"To":[1],"report":[2],"long-term":[3],"efficacy":[4,45,72,289],"of":[5,35,141,154,172,216,238,273,304,314,325,335,348,358,369,379,390,400,419,443,467,492,518,542,566,590,614,639,664,681,692,703,714,726,737,748,759,777,795,813,831,850,868,886,904,922,940,958,980,991,1030,1044,1056,1082,1100,1151,1170,1190,1200,1212],"evobrutinib":[6,85,121,192,261,294],"in":[7,46,52,149,164,179,185,258,311,332,355,376,397,416,440,464,489,515,539,563,587,611,636,661,774,792,810,828,847,865,883,901,919,937,955,1053,1079,1097,1148,1167,1187,1209],"patients":[8,83,114,150,162,189,239,281],"with":[9,32,182,260,1070,1159,1178,1198,1220],"relapsing":[10,47],"multiple":[11,48],"sclerosis":[12,49],"over":[13],"combined":[14],"randomized":[15,163],"and":[16,40,138,142,206,225,274],"open-label":[17],"extension":[18],"(OLE)":[19],"study":[20],"periods.":[21],"Background:":[22],"Evobrutinib":[23],"is":[24],"a":[25,53,241,319,340,363,384,405,424,448,472,497,523,547,571,595,619,644,669,782,800,818,836,855,873,891,909,927,945,963,1061,1087,1105,1118,1134,1156,1175,1195,1217],"highly":[26],"selective":[27],"Bruton\u2019s":[28],"tyrosine":[29],"kinase":[30],"inhibitor":[31],"dual":[33],"mode":[34],"action,":[36],"targeting":[37],"B":[38],"cells":[39],"myeloid":[41],"cells.":[42],"Evobrutinib\u2019s":[43],"clinical":[44],"was":[50,120,131,243,267],"shown":[51],"Phase":[54],"II,":[55],"randomized,":[56],"controlled":[57],"trial":[58],"NCT02975349:":[59],"T1":[60],"Gd-enhancing":[61],"lesions":[62],"significantly":[63],"decreased":[64],"versus":[65,254],"placebo":[66,93,104],"at":[67,203,210,222,229,264,269],"Week":[68,75,112,204,211,223,230,265,270],"24":[69,95],"(primary":[70],"endpoint);":[71],"continued":[73],"through":[74],"48.":[76],"Design/Methods:":[77],"During":[78],"the":[79,103,117,165,170,312,333,356,377,398,417,441,465,490,516,540,564,588,612,637,662,775,793,811,829,848,866,884,902,920,938,956,1054,1080,1098,1149,1168,1188,1210],"double-blind":[80],"period":[81],"(DBP),":[82],"received":[84,308,329,352,373,394,413,437,461,486,512,536,560,584,608,633,658,685,696,707,718,730,741,752,763,771,789,807,825,844,862,880,898,916,934,952,970,984,995,1022,1036,1050,1076,1094,1113,1129,1145,1164,1184,1206],"25mg":[86,109,295],"QD,":[87,89,296,298],"75mg":[88,90,122,128,193,252,262,284,297],"BID,":[91],"or":[92,157,299,427,451,475,500,526,550,574,598,622,647,672,972,1120,1136],"for":[94,248,316,321,337,342,360,365,381,386,402,407,421,432,445,456,469,480,494,505,520,531,544,555,568,579,592,603,616,627,641,652,666,677,779,784,797,802,815,820,833,838,852,857,870,875,888,893,906,911,924,929,942,947,960,965,1025,1039,1058,1067,1084,1089,1102,1107,1153,1172,1192,1214],"weeks,":[96,101],"continuing":[97],"treatment":[98,156,288],"until":[99],"48":[100,205,224,266],"except":[102],"group,":[105],"who":[106],"switched":[107],"to":[108,144,276,1005,1011,1017,1123,1139],"QD.":[110],"At":[111],"48,":[113],"could":[115],"enter":[116],"OLE.":[118],"Treatment":[119],"QD":[123],"(median":[124],"\u224848":[125],"weeks),":[126],"then":[127],"BID.":[129],"Efficacy":[130],"assessed":[132],"by":[133,235],"annualized":[134],"relapse":[135,147],"rate":[136],"(ARR),":[137],"cumulative":[139,214],"probability":[140,215],"time":[143,234,275],"first":[145,217,277],"qualified":[146],"(QR)":[148],"completing":[151],"\u226560":[152],"weeks":[153,178],"OLE":[155],"discontinuing.":[158],"Results:":[159],"Of":[160],"213":[161],"DBP,":[166],"164":[167],"(77%)":[168],"entered":[169],"OLE;":[171],"these,":[173],"148":[174],"(90%)":[175],"completed":[176],"\u2265108":[177],"total.":[180],"Compared":[181],"those":[183,249,291],"initiated":[184,190,250,282,292],"other":[186],"DBP":[187],"arms,":[188],"on":[191,251,283,293,423,447,471,496,522,546,570,594,618,643,668],"BID":[194,253,263,285],"had:":[195],"lower":[196,213],"ARR":[197,259],"(95%":[198],"CI),":[199],"0.11":[200],"(0.04,":[201],"0.25)":[202],"0.12":[207],"(0.06,":[208],"0.22)":[209],"108;":[212],"QR,":[218],"0.08":[219],"(0.00,":[220],"0.16)":[221],"0.20":[226],"(0.08,":[227],"0.31)":[228],"96.":[231],"The":[232,302,323,346,367,388,679,690,701,712,724,735,746,757,978,989],"estimated":[233],"which":[236],"20%":[237],"had":[240],"QR":[242,278],"almost":[244],"three":[245],"times":[246],"longer":[247],"placebo.":[255,300],"Conclusions:":[256],"Improvement":[257],"maintained":[268],"108.":[271],"Probability":[272],"highlighted":[279],"that":[280],"achieved":[286],"greater":[287],"than":[290],"Disclosure:":[301],"institution":[303,324,347,368,389,680,691,702,713,725,736,747,758,979,990],"Dr.":[305,326,349,370,391,410,434,458,483,509,533,557,581,605,630,655,682,693,704,715,727,738,749,760,768,786,804,822,841,859,877,895,913,931,949,967,981,992,1033,1047,1073,1091,1110,1126,1142,1161,1181,1203],"Montalban":[306,327,350,371,392,411,435,459,484,510,534,558,582,606,631,656,683,694,705,716,728,739,750,761],"has":[307,328,351,372,393,412,436,460,485,511,535,559,583,607,632,657,684,695,706,717,729,740,751,762,770,788,806,824,843,861,879,897,915,933,951,969,983,994,1003,1009,1015,1021,1035,1049,1075,1093,1112,1128,1144,1163,1183,1205],"personal":[309,330,353,374,395,414,438,462,487,513,537,561,585,609,634,659,772,790,808,826,845,863,881,899,917,935,953,1023,1037,1051,1077,1095,1146,1165,1185,1207],"compensation":[310,331,354,375,396,415,439,463,488,514,538,562,586,610,635,660,773,791,809,827,846,864,882,900,918,936,954,1024,1038,1052,1078,1096,1147,1166,1186,1208],"range":[313,334,357,378,399,418,442,466,491,517,541,565,589,613,638,663,776,794,812,830,849,867,885,903,921,939,957,1055,1081,1099,1150,1169,1189,1211],"$500-$4,999":[315,359,380,420,493,543,567,591,640,778,814,832,851,887,923,1171,1191,1213],"serving":[317,338,361,382,403,422,446,470,495,521,545,569,593,617,642,667,780,798,816,834,853,871,889,907,925,943,961,1026,1040,1059,1085,1103,1154,1173,1193,1215],"as":[318,339,362,383,404,781,799,817,835,854,872,890,908,926,944,962,1027,1041,1060,1086,1104,1155,1174,1194,1216],"Consultant":[320,341,364,385,406,783,801,819,837,856,874,892,910,928,946,964,1088,1106],"Biogen.":[322,457,700,803],"$5,000-$9,999":[336,401,444,468,519,615,665,869,959,1083],"Merck/":[343,506],"EMD":[344,507,1031,1045,1071],"Serono.":[345,508,1032,1046,1072],"Medday.":[366,556,711],"Novartis.":[387,604,756,912,988],"Hoffmann-La":[408,628,722],"Roche.":[409,629,723,948],"Scientific":[425,449,473,498,524,548,572,596,620,645,670],"Advisory":[426,450,474,499,525,549,573,597,621,646,671],"Data":[428,452,476,501,527,551,575,599,623,648,673],"Safety":[429,453,477,502,528,552,576,600,624,649,674],"Monitoring":[430,454,478,503,529,553,577,601,625,650,675],"board":[431,455,479,504,530,554,578,602,626,651,676],"Alexion.":[433,785],"Celgene/":[481],"Receptos.":[482],"Genzyme.":[532],"Nervgen.":[580],"TG":[653],"Therapeutics.":[654,840],"Sanofi-Genzyme.":[678],"research":[686,697,708,719,731,742,753,764,985,996],"support":[687,698,709,720,732,743,754,765,986,997],"from":[688,699,710,721,733,744,755,766,976,987,998,1117,1133],"Abbvie.":[689],"Sanofi.":[734,966],"Merck.":[745,894],"Teva.":[767],"Arnold":[769,787,805,823,842,860,878,896,914,932,950,968,982,993],"$10,000-$49,999":[796,905,941,1101,1152],"Celgene.":[821],"Frequency":[839],"GENeuro.":[858],"Genentech.":[876],"Receptos/Celgene.":[930],"stock":[971],"an":[973,1028,1042],"ownership":[974],"interest":[975],"NeuroRx.":[977],"Immunotec.":[999],"Martin":[1000,1020],"Weber,":[1001],"MD":[1002],"nothing":[1004,1010,1016],"disclose.":[1006,1012,1018],"Ivan":[1007],"Staikov":[1008],"Karolina":[1013],"Piasecka-Stryczynska":[1014],"Emily":[1019],"employee":[1029,1043],"Mandel":[1034],"Dangond":[1048],"$1,000,000+":[1057],"Head,":[1062],"Global":[1063],"Clinical":[1064],"Development":[1065],"(employee":[1066],"12":[1068],"years)":[1069],"Wolinsky":[1074,1092,1111,1127,1143,1162,1182,1204],"Alkermes.":[1090],"GW":[1108],"Pharma.":[1109],"intellectual":[1114,1130],"property":[1115,1131],"interests":[1116,1132],"discovery":[1119,1135],"technology":[1121,1137],"relating":[1122,1138],"health":[1124,1140],"care.":[1125,1141],"CME":[1157,1176,1196,1218],"Lectures":[1158,1177,1197,1219],"AcademicCME.":[1160],"Annenberg":[1179],"Center.":[1180],"Consortium":[1199],"MS":[1201],"Centers.":[1202],"PRIME.":[1221]},"counts_by_year":[{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":3},{"year":2021,"cited_by_count":1}],"updated_date":"2026-10-27T15:51:10.671819","created_date":"2021-10-25T00:00:00"}